Puma Biotechnology, Inc. (PBYI)
10.29
+0.32
(+3.21%)
USD |
NASDAQ |
Oct 09, 16:00
10.29
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology Cash from Operations (Quarterly) : 1.624M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.624M |
| March 31, 2026 | 15.42M |
| December 31, 2025 | 14.42M |
| September 30, 2025 | 9.689M |
| June 30, 2025 | 14.08M |
| March 31, 2025 | 3.612M |
| December 31, 2024 | 15.61M |
| September 30, 2024 | 11.04M |
| June 30, 2024 | 1.027M |
| March 31, 2024 | 11.25M |
| December 31, 2023 | 10.46M |
| September 30, 2023 | 10.62M |
| June 30, 2023 | 3.296M |
| March 31, 2023 | 2.643M |
| December 31, 2022 | 7.683M |
| September 30, 2022 | 17.26M |
| June 30, 2022 | -13.87M |
| March 31, 2022 | -26.90M |
| December 31, 2021 | -5.435M |
| September 30, 2021 | 10.50M |
| June 30, 2021 | -0.074M |
| March 31, 2021 | 15.66M |
| December 31, 2020 | -5.635M |
| September 30, 2020 | 1.72M |
| June 30, 2020 | 16.23M |
| Date | Value |
|---|---|
| March 31, 2020 | -11.54M |
| December 31, 2019 | 1.566M |
| September 30, 2019 | -7.307M |
| June 30, 2019 | 44.25M |
| March 31, 2019 | -16.13M |
| December 31, 2018 | 7.047M |
| September 30, 2018 | -7.262M |
| June 30, 2018 | -17.64M |
| March 31, 2018 | -6.253M |
| December 31, 2017 | -35.61M |
| September 30, 2017 | -54.91M |
| June 30, 2017 | -45.91M |
| March 31, 2017 | -36.04M |
| December 31, 2016 | -40.96M |
| September 30, 2016 | -34.89M |
| June 30, 2016 | -30.81M |
| March 31, 2016 | -35.03M |
| December 31, 2015 | -33.03M |
| September 30, 2015 | -36.87M |
| June 30, 2015 | -34.55M |
| March 31, 2015 | -50.02M |
| December 31, 2014 | -18.46M |
| September 30, 2014 | -24.32M |
| June 30, 2014 | -17.37M |
| March 31, 2014 | -17.05M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | -0.684M |
| Arcutis Biotherapeutics, Inc. | 12.64M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Savara, Inc. | -29.75M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 7.972M |
| Cash from Financing (Quarterly) | -11.34M |
| Free Cash Flow | 41.16M |
| Free Cash Flow Per Share (Quarterly) | 0.0309 |
| Free Cash Flow to Equity (Quarterly) | 12.76M |
| Free Cash Flow to Firm (Quarterly) | 1.803M |
| Free Cash Flow Yield | 7.77% |